Overview
- More than 100 MPs from CDU/CSU, SPD, Greens and the Left filed a motion for systemwide monitoring and an expert panel to review how non‑invasive prenatal tests are used and reimbursed.
- The Bundestag debated the motion on March 20 and sent it to committees for further consideration, leaving existing rules unchanged for now.
- Barmer insurer data cited in the motion show uptake rising from 32% in 2023 to nearly 50% in 2024, indicating de facto routine use despite the GBA’s non‑screening intent.
- Reports of higher-than-expected false positives and increased invasive follow-ups fueled calls for oversight, while medical bodies defended access with rigorous counselling and informed consent.
- The initiative seeks clearer indication criteria and transparent reporting, with some proponents aiming to publish monitoring results by June 30, 2027.